Cargando…

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%

PURPOSE: To examine the pooled per-protocol ocular end points from two conjunctival allergen challenge (CAC) clinical trials of the dual-action antihistamine bepotastine besilate ophthalmic solution (BBOS) 1.5%. METHODS: Two Phase III, placebo-controlled, double-masked, randomized clinical trials we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergmann, Mark T, Williams, Jon I, Gomes, Paul J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140238/ https://www.ncbi.nlm.nih.gov/pubmed/25152611 http://dx.doi.org/10.2147/OPTH.S66637

Ejemplares similares

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
por: Marini, María Cecilia, et al.
Publicado: (2023)

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
por: Wingard, Jeremy B, et al.
Publicado: (2011)

Novel Functional Aspect of Antihistamines: The Impact of Bepotastine Besilate on Substance P-Induced Events
por: Kitaba, Shun, et al.
Publicado: (2009)

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital
por: Sruthi, Vadlakonda, et al.
Publicado: (2020)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Williams, Patricia B, et al.
Publicado: (2010)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
por: Cervantes, Lorenzo J, et al.
Publicado: (2011)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
por: Schultz, Clyde
Publicado: (2012)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Allergic conjunctivitis
por: Rathi, Varsha M, et al.
Publicado: (2017)

Baricitinib/cisatracurium besilate: Rhabdomyolysis: case report
Publicado: (2021)

Bepotastine-induced urticaria, cross-reactive with other antihistamines
por: Kang, Ju Wan, et al.
Publicado: (2016)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Continuously protracted infusion of cisatracurium besilate in patients with ARDS
por: Yuan, Ziming, et al.
Publicado: (2022)

Cisatracurium-besilate: ICU-acquired weakness: case report
Publicado: (2022)

Recognition of allergic conjunctivitis in patients with allergic rhinitis
por: Williams, Daniel C, et al.
Publicado: (2013)

Therapeutic Targets in Allergic Conjunctivitis
por: Labib, Bisant A., et al.
Publicado: (2022)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Allergic conjunctivitis in Asia
por: Thong, Bernard Yu-Hor
Publicado: (2017)

Effects of bepotastine, a nonsedating H1-antihistamine, for the treatment of persistent cough and allergic rhinitis: a randomised, double-blind, placebo-controlled trial
por: Lee, Ji-Hyang, et al.
Publicado: (2023)

Simultaneous Estimation of Amlodipine Besilate and Olmesartan Medoxomil in Pharmaceutical Dosage Form
por: Wankhede, S. B., et al.
Publicado: (2009)

Allergic conjunctivitis in Jos-Nigeria
por: Malu, Keziah N.
Publicado: (2014)

Current Knowledge in Allergic Conjunctivitis
por: Villegas, Beatriz Vidal, et al.
Publicado: (2021)

Diagnostic approach and grading scheme for canine allergic conjunctivitis
por: Delgado, Esmeralda, et al.
Publicado: (2023)

Cisatracurium besilate/dexamethasone/remdesivir: Malignant hyperthermia and lack of efficacy: case report
Publicado: (2021)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) - review
por: Iordache, Andreea, et al.
Publicado: (2022)

359 Prevalence of Allergic Conjunctivitis in Childhood
por: Geraldini, Marcos, et al.
Publicado: (2012)

A contemporary look at allergic conjunctivitis
por: Dupuis, Pascale, et al.
Publicado: (2020)

Corneal biomechanical changes in allergic conjunctivitis
por: Wang, Qian, et al.
Publicado: (2021)

Spectrophotometric and HPLC Methods for Simultaneous Estimation of Amlodipine Besilate, Losartan Potassium and Hydrochlorothiazide in Tablets
por: Wankhede, S. B., et al.
Publicado: (2010)

Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure
por: Kanzaki, Sho, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l25al2h57da9b7g6g3r2o2qct7